AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A compound of the formula Y:



Y

where;

R_1 is O, S;

R_2 is pyrid-2-yl, substituted at the 5 position with the $-(CHR_{11})_p$-E-$(CHR_{11})_q$-R_{10} moiety~~a nitrogen-containing heterocycle, wherein a nitrogen is located at the 2 position relative to the (thio)urea bond~~;

R_3 is H~~, C_1-C_3 alkyl,~~

~~R_4-R_7~~R_4 and R_7 are fluoro~~independently selected from H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, haloC_1-C_6 alkyl, C_1-C_6 alkanoyl, haloC_1-C_6 alkanoyl, C_1-C_6 alkoxy, haloC_1-C_6 alkoxy, C_1-C_6 alkyloxy-C_1-C_6 alkyl, haloC_1-C_6 alkyloxyC_1-C_6 alkyl, hydroxyC_1-C_6 alkyl, aminoC_1-C_6 alkyl, carboxyC_1-C_6 alkyl, cyanoC_1-C_6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto~~;

R_5 and R_6 are H;

X is $-(CR_8R_8')_n$-D-$(CR_8R_8')_m$-;

D is~~a bond, $-NR_9$-, -O-, -S-, -S(=O)- or $-S(=O)_2$-~~;

m is 1

n ~~and m are independently~~is 0~~, 1 or 2, provided that they are not both 0 when D is a bond~~;

R_8 and R_8' are ~~independently H, C_1-C_3 alkyl, haloC_1-C_3alkyl, hydroxy, or R_8 and R_8' together with their adjacent C atom is –C(=O)-~~;

~~R_9 is independently H, C_1-C_3 alkyl;~~

E is ~~-CH_2-, -CHOH-, -C(=O)-, -NR_9-, -O-, -S-, -$S(=O)_2$-~~;

p and q are ~~independently 0, 1 or 2, where p+q ≤ 2~~;

R_{10} is pyrid-3-yl, optionally substituted with halo or cyano~~an optionally substituted, saturated or unsaturated 5-7 membered carbocyclic ring or an optionally substituted, saturated or unsaturated 5-7 membered heterocyclic ring containing 1 to 3 hetero atoms selected from O, N and S~~;

~~R_{11} is independently H, C_1-C_3 alkyl, haloC_1-C_3alkyl, hydroxy~~

~~with the proviso that –$(CHR_{11})_p$-E-$(CHR_{11})_q$-R_{10} is not unsubstituted phenoxy;~~

and pharmaceutically acceptable salts and prodrugs thereof.

2. **(Original)** A compound according to claim 1, wherein R_1 is O.

3. **Canceled**

4. **Canceled**

5. **Canceled**

6. **(Original)** A compound according to claim 1, wherein the cyclopropyl moiety has an enantiomeric excess of the conformation depicted in the partial formulae:



where X is as defined, Y is the bridge to the (substituted) phenyl ring depicted in formula I and Z is bond to the urea-R_2-$(CHR_{11})_p$-E-$(CHR_{11})_q$-R_{10} moiety depicted in formula I.

7. **(Original)** A compound according to claim 1 wherein the compound of formula I compises an enantiomeric excess of the isomer showing negative optical activity.

8. – 26. **Canceled**

27. **(Currently Amended)** A compound according to claim 1~~2~~6, wherein R_{10} is cyano or fluoro substituted pyrid-3-yl ~~or pyrid-4-yl~~.

28. **(Currently Amended)** A pharmaceutical composition comprising a compound as defined in any ~~preceding~~ one of claims 1, 6, 7, 9 and 27, and a pharmaceutically acceptable vehicle or diluent therefor.

29. **(Currently Amended)** A composition according to claim 28, further comprising 1 to 3 additional HIV antivirals selected from the group consisting of AZT, ddI, ddC, D4T, 3TC, DAPD, alovudine, abacavir, adefovir, adefovir dipivoxil, bis-POC-PMPA, foscarnet, efavirenz, trovirdine, capravirine, nevirapine, delaviridine, tipranavir, emtricitabine, omaciclovir, valomaciclovir stearate, TMC-126, TMC-125, TMC-120, efavirenz, loviride, ritonavir, kaletra, lopinavir, saquinavir, lasinavir, indinavir, amprenavir, amprenavir phosphate and nelfinavir.

30. **(Currently Amended)** A method of treatment ~~or prophylaxis~~ of HIV-1 infections comprising administering to a patient infected with HIV-1 an effective amount of the compound as defined by claim 1.

31. **(Previously Presented)** The method of claim 30, wherein said HIV-1 infection is a drug escape mutant.

32. **(Previously Presented)** The method of claim 31, wherein said drug escape mutant comprises the K103I mutation.

33. (**NEW**) The method of claim 30, wherein the compound has the formula:



34. (**NEW**) A compound according to claim 27, wherein R_{10} is 6-cyano-pyrid-3-yl.

35. (**NEW**) The compound of claim 1 with the formula:



36. (**NEW**) A pharmaceutical composition comprising the compound of claim 34 and a pharmaceutically acceptable vehicle or diluent therefor.

37. (**NEW**) The pharmaceutical composition of claim 35, further comprising 1-3 additional antivirals selected from the group consisting of AZT, ddI, ddC, D4T, 3TC, DAPD, alovudine, abacavir, adefovir, adefovir dipivoxil, bis-POC-PMPA, foscarnet, efavirenz, trovirdine, capravirine, nevirapine, delaviridine, tipranavir, emtricitabine, omaciclovir, valomaciclovir stearate, TMC-126, TMC-125, TMC-120, efavirenz, loviride, ritonavir, kaletra, lopinavir, saquinavir, lasinavir, indinavir, amprenavir, amprenavir phosphate, and nelfinavir.